Emergent BioSolutions (NYSE:EBS) Shares Down 11%

Emergent BioSolutions Inc. (NYSE:EBS) traded down 11% during mid-day trading on Thursday . The company traded as low as $11.14 and last traded at $11.31. 1,027,926 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 3,796,579 shares. The stock had previously closed at $12.71.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of Emergent BioSolutions in a report on Tuesday, July 2nd.

Emergent BioSolutions Stock Performance

The stock’s fifty day moving average price is $8.40 and its two-hundred day moving average price is $4.66. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.08. The company has a market cap of $529.76 million, a P/E ratio of -0.92 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of ($3.65) by $4.24. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. The company had revenue of $300.40 million during the quarter. During the same period last year, the company posted ($3.17) EPS. As a group, equities analysts predict that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current year.

Insider Transactions at Emergent BioSolutions

In related news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now directly owns 54,482 shares in the company, valued at approximately $332,885.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 12,919 shares of company stock valued at $75,831. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Emergent BioSolutions

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after purchasing an additional 436,911 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Emergent BioSolutions by 84.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock valued at $6,898,000 after acquiring an additional 1,312,934 shares during the period. Assenagon Asset Management S.A. increased its position in Emergent BioSolutions by 0.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 839,414 shares of the biopharmaceutical company’s stock valued at $2,124,000 after acquiring an additional 5,042 shares during the period. Allspring Global Investments Holdings LLC increased its position in Emergent BioSolutions by 1.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock valued at $1,105,000 after acquiring an additional 6,724 shares during the period. Finally, Los Angeles Capital Management LLC increased its position in Emergent BioSolutions by 20.1% in the 1st quarter. Los Angeles Capital Management LLC now owns 193,991 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 32,460 shares during the period. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.